Erasca, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ERAS Nasdaq 2836 www.erasca.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Erasca, Inc.

Erasca (ERAS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Nov 15th, 2024 2:55 pm
Erasca Reports Third Quarter 2024 Business Updates and Financial Results - Nov 12th, 2024 9:01 pm
Erasca to Present at Upcoming Investor Conferences - Nov 5th, 2024 1:00 pm
Erasca Insiders Added US$1.95m Of Stock To Their Holdings - Oct 30th, 2024 3:19 pm
Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise - Oct 24th, 2024 12:00 pm
Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium - Sep 25th, 2024 12:00 pm
Erasca, Inc. (NASDAQ:ERAS) is favoured by institutional owners who hold 61% of the company - Sep 23rd, 2024 2:09 pm
Erasca to Present at Upcoming Investor Conferences in September - Aug 29th, 2024 12:00 pm
We're Hopeful That Erasca (NASDAQ:ERAS) Will Use Its Cash Wisely - Aug 14th, 2024 10:46 am
Erasca Reports Second Quarter 2024 Business Updates and Financial Results - Aug 12th, 2024 8:01 pm
Erasca kicks off Phase III trial for naporafenib combo therapy in melanoma - Jun 18th, 2024 4:14 pm
Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma - Jun 18th, 2024 12:00 pm
Should You Buy Erasca, Inc. (ERAS) After Golden Cross? - Jun 4th, 2024 1:55 pm
Erasca to Present at Upcoming Investor Conferences in June - May 29th, 2024 12:00 pm
Independent Director of Erasca Picks Up 14% More Stock - May 23rd, 2024 11:00 am
Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares - May 21st, 2024 8:05 pm
Erasca restructures; Novartis moves to complete MorphoSys deal - May 17th, 2024 9:51 am
Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise - May 17th, 2024 12:02 am
Erasca Announces Pricing of Underwritten Offering of Common Stock - May 17th, 2024 12:00 am
Erasca Reports First Quarter 2024 Business Updates and Financial Results - May 8th, 2024 8:01 pm